Home
overview
A unique opportunity to learn from leading industry experts including:
Dr Roy Bullingham, Vice President, Global Clinical Pharmacology, Pharmacia/Pfizer
Dr Peter McIntyre, Laboratory Head/Program Team Head, Novartis
Prof Odd-Geir Berge, Associate Director, In Vivo Pharmacology, AstraZeneca
Dr Mark Field, Manager, Pain Therapeutics, Pfizer
Kirk Johnson, Head, Neuroscience Research, Eli Lilly
Dr Theo Meert, Disease Area Head & Research Fellow, CNS Pain & Alzheimer, Johnson & Johnson
Dr Kirsten Arndt, Head, Laboratory, CNS Research, Boehringer Ingelheim
Dr Hans Quiding, Senior Research Scientist, AstraZeneca
Dr Steven England, Principal Scientist, Pfizer
Dr Katharine Walker, Director, Neuropharmacology, Purdue Pharma
Dr Gordon Ng, Research Scientist, Neurology, Amgen

Benefits of attending:
ADVANCES IN PAIN THERAPEUTICS: keep up to date with the very latest research
HUMAN/ANIMAL MODELS: understand the need for effective modelling systems
DRUG DISCOVERY: find out about possible new targets for treating pain
TARGET VALIDATION: look at novel techniques for validating potential targets
CLINICAL TRIALS: learn about new approaches to clinical study design
MARKET OPPORTUNITIES: discover the key factors for success of emerging therapies

“Growth of the analgesia market is dependent on the introduction of new products. The future of pain therapeutics is bright and the opportunity for investment, biotechnology and pharmaceutical companies to partner in value creation is significant”
Dr Phillip Birch, Chief Scientific Officer, Ionix Pharmaceuticals

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Richard Carter

Dr Richard Carter, Managing Director, NeuroBioMedica

9:10 OPPORTUNITIES IN PAIN THERAPEUTICS

Dr Steven England

Dr Steven England, Principal Scientist, Pfizer

  • Market opportunity
  • Issues with existing therapies
  • Unmet medical need
  • Key factors for success
  • Emerging therapies
  • The future for pain relief
  • 9:40 TRP CHANNEL THERMORECEPTORS AS TARGETS FOR CHRONIC PAIN

    Dr Peter McIntyre

    Dr Peter McIntyre, Laboratory Head/Program Team Head, Novartis

  • The TrpV1 blocker capsazepine (CPZ) shows species selectivity with respect to some of its actions
  • CPZ is anti-hyperalgesic when assayed in a susceptible species
  • Other TrpV1 blockers may be anti-hyperalgesic
  • We and others have discovered other Trp channel thermoreceptors in sensory neurones and skin
  • The possibility that these may be involved in pain sensation
  • 10:20 TARGET VALIDATION FOR NEW ANALGESIC TARGETS

    Prof John Wood

    Prof John Wood, Professor, Molecular Neuroscience, University College London

  • Targeted gene deletion
  • Peripheral vs central targets
  • Sodium channels and pain pathways
  • 11:00 Morning Coffee

    11:20 PRECLINICAL MODELS

    Dr Mark Field

    Dr Mark Field, Manager, Pain Therapeutics, Pfizer

  • Challenges in developing preclinical models
  • From simple to complex models of pain
  • Measuring clinically relevant symptoms
  • How effective are preclinical models?
  • 12:00 ANIMAL PAIN MODELS

    Prof Odd-Geir Berge

    Prof Odd-Geir Berge, Associate Director, In Vivo Pharmacology, AstraZeneca

  • General discussion: validity of animal models
  • Difficulties in assessing pain in animals
  • How effective are animal models?
  • The use of animals to screen putative analgesics
  • Animals models to investigate the causes of pain
  • 12:40 Networking Lunch

    13:40 CHRONIC PAIN AND BONE DISEASE

    Dr Katharine Walker

    Dr Katharine Walker, Director, Neuropharmacology, Purdue Pharma

  • Clinical perspectives on chronic pain associated with bone disease
  • Existing therapies
  • Unmet medical needs
  • Pre-clinical models of chronic 'bone-related' pain
  • 14:20 HUMAN EXPERIMENTAL PAIN MODELS

    Dr Hans Quiding

    Dr Hans Quiding, Senior Research Scientist, AstraZeneca

  • Why human experimental pain models?
  • Examples of pain models
  • Examples of variables in pain models
  • Examples of drug effects in pain models
  • 15:00 OPIOID ANALGESICS

    Dr Theo Meert

    Dr Theo Meert, Research Fellow, Head of Department, CNS – Pain & Alzheimer’s, Johnson & Johnson

  • Comparison of opioids
  • Role of routes of administration/techniques
  • Combination treatments to reduce opioid requirements
  • Reducing opioid side-effects
  • 15:40 Afternoon Tea

    16:00 CANNABIS-BASED MEDICINES

    Dr Nicos Sarantis

    Dr Nicos Sarantis, Clinical Development Director, GW Pharmaceuticals

  • Clinical trials of cannabis-based medicines in pain
  • Safety of cannabis-based medicines
  • The place of cannabis-based medicines in the management of pain
  • 16:40 DEVELOPMENT OF AN EXTENDED RELEASE ANALGESIC

    Dr Sylvie Bouchard

    Dr Sylvie Bouchard, Vice President, Clinical Development, Labopharm

    17:20 MARKET OPPORTUNITIES IN CHRONIC LOWER BACK PAIN

    Dr Nancy MacDonald

    Dr Nancy MacDonald, Analyst, Decision Resources

  • Epidemiology of CLBP
  • Current therapy and unmet needs
  • Drug development activity
  • Market outlook
  • Key challenges and opportunities
  • 18:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Phillip Birch

    Dr Phillip Birch, Chief Scientific Officer, Ionix Pharmaceuticals

    9:10 MIGRAINE

    Kirk Johnson

    Kirk Johnson, Head, Neuroscience Research, Eli Lilly

  • Pathophysiology of migraine
  • Animal models of migraine
  • Current migraine therapies and pharmacological tools
  • Using animal models to predict novel therapies
  • Emerging therapies
  • 9:40 MIGRAINE PAIN: THE ROLE OF CGRP

    Dr Kirsten Arndt

    Dr Kirsten Arndt, Head, Laboratory, CNS Research, Boehringer Ingelheim

  • Migraine pathophysiology
  • Current treatment
  • The role of vasodilation in migraine
  • The neuropeptide CGRP and its receptors
  • In vitro and in vivo pharmacological profile of BIBN4096, a potent CGRP receptor antagonist
  • 10:20 NEW APPROACHES TO INFLAMMATORY AND NEUROPATHIC PAIN

  • Decreases mechanical and thermal hyperalgesia
  • Reduces pro-inflammatory cytokine levels induced by endotoxin challenge
  • Reduces mechanical allodynia and heat hyperalgesia in CCI and SNI models
  • Reduces capsaicin induced pain-related behaviour
  • Prof Anthony Rees

    Prof Anthony Rees, , Director, Science, Synt:em

    Dr Bared Safieh-Garebedian

    Dr Bared Safieh-Garebedian, Associate Professor, American University of Beirut, Lebanon

    11:00 Morning Coffee

    11:20 TOPICAL APPROACHES TO THE MANAGEMENT OF NEUROPATHIC PAIN

    Dr Keith Bley

    Dr Keith Bley, Senior Vice President, Nonclinical Research & Development, NeurogesX

  • Role of cutaneous nociceptors in pain initiation and maintenance
  • Central versus peripheral mechanisms
  • Topical lidocaine-based therapies
  • Topical capsaicin-based therapies
  • Recent clinical data
  • 12:00 BIOMARKERS IN PAIN RESEARCH

    Dr Gordon Ng

    Dr Gordon Ng, Research Scientist, Neurology, Amgen

  • Rodent pain models for target validation
  • Identifying biomarkers for pain targets
  • Imaging, skin and blood biomarker assays
  • Application of biomarkers for preclinical development
  • Application of biomarkers in the clinic
  • 12:40 Networking Lunch

    14:00 VALIDATING DRUG TARGETS FOR PAIN IN MAN

    Prof Praveen Anand

    Prof Praveen Anand, Professor, Clinical Neurology, Imperial College London

  • Lessons from failed clinical trials
  • Limitations of volunteer models
  • Relating neuropathology of novel targets to function in humans
  • Selecting patients and end-points based on target validation
  • Value of ‘experimental’ Phase IIa trials
  • 14:40 CURRENT REGULATORY INITIATIVES IN ANALGESIA

    Dr Najib Babul

    Dr Najib Babul, Chief Executive Officer, TheraQuest Biosciences

  • Review current state of analgesic drug development
  • Identify current regulatory and scientific initiatives
  • Challenges in analgesic drug development
  • Potential solutions to current challenges
  • 15:20 Afternoon Tea

    15:40 DRUG DISCOVERY AND DEVELOPMENT

    Dr Phillip Birch

    Dr Phillip Birch, Chief Scientific Officer, Ionix Pharmaceuticals

  • Investing in new classes of analgesic drugs
  • Building a balanced risk product portfolio
  • Establishing partnerships to drive development
  • Commercialisation opportunities
  • 16:20 INTRANASAL DRUG DELIVERY FOR PAIN THERAPEUTICS

    Dr Gordon Brandt

    Dr Gordon Brandt, Executive Vice President, Science & Clinical Development, Nastech Pharmaceuticals

  • The unique advantages to intranasal delivery of pain therapeutics · Very fast onset of action · Absence of first pass metabolism · Potential for preferential CNS delivery · Needleless delivery
  • The advantages of Nastech’s formulation science · High-throughput in vitro screening systems to evaluate safety and efficacy of candidate formulations · Ongoing research into the molecular biology of tight junction modulation · 20 years work developing proprietary intranasal formulations
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.